Sectors

Data Insights

Venglustat malate by Sanofi for Gaucher Disease Type III: Likelihood of Approval

Data Insights

LIOCYXM-004 by Lion TCR for Hepatocellular Carcinoma: Likelihood of Approval

Data Insights

EVX-02 by Evaxion Biotech for Melanoma: Likelihood of Approval

Data Insights

SBT-101 by SwanBio Therapeutics for Adrenomyeloneuropathy (AMN): Likelihood of Approval

Data Insights

TDM-105795 by Technoderma Medicines for Androgenic Alopecia: Likelihood of Approval

Data Insights

(Chlorthalidone + losartan) by Laboratorios Silanes for Idiopathic (Essential) Hypertension: Likelihood of Approval

Data Insights

SHJ-002 by Sunhawk Vision Biotech for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval

Data Insights

Alimta by Eli Lilly and Co for Chordoma: Likelihood of Approval

Clinical Trials

News

Invenra’s antibody gains US FDA designations for neuroblastoma treatment

News

Dr Reddy’s, Aurigene and Kainomyx to co-develop anti-malarials

News

Daiichi Sankyo-AstraZeneca’s ENHERTU gains BTD for breast cancer

Drug Manufacturers

Buyer's Guides

Oral Solid Dose Manufacturing Companies in the Pharmaceutical Industry

Analyst Comment

FDA hits Ozempic and Mounjaro counterfeit compounders with warning letters

GlobalData Healthcare

News

Telix acquires RLS Radiopharmacies to expand US manufacturing presence

Therapy Area

News

Shattuck Labs stock craters following pipeline and job cuts

Phalguni Deswal

News

Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec exec

News

Fresenius Kabi wins FDA approval for Stelara biosimilar Otulfi

Pricing and Market Access

Analyst Comment

Keytruda and Opdivo: a decade review

Analyst Comment

US negotiations for first round of drugs reveal $6bn in Medicare savings

Analyst Comment

Colombia’s president signs law to strengthen pharmaceutical sector

Daniela Morales

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close